Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dopamine beta-hydroxylase (DBH) is an enzyme crucial for catecholamine biosynthesis, specifically catalyzing the conversion of dopamine to norepinephrine (noradrenaline). This reaction represents a key step in the metabolic pathway that produces neurotransmitters essential for nervous system function and hormonal regulation. Variants or mutations in the *DBH* gene can lead to reduced or absent enzyme activity, resulting in dopamine beta-hydroxylase deficiency.
Catalyzes the conversion of dopamine to norepinephrine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dopamine beta-hydroxylase (DBH).